ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Approaching Gold-Standard Sensitivity in a Portable and Versatile Gold Nanoprisms Thermoplasmonic Platform for Lateral Flow Detection of Biomolecules.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Approaching Gold-Standard Sensitivity in a Portable and Versatile Gold Nanoprisms Thermoplasmonic Platform for Lateral Flow Detection of Biomolecules.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Plasmonic nanoparticles exhibit unique optical and thermal properties that make them ideal for next-generation diagnostic technologies. Among them, gold nanoprisms (AuNPrs) are especially powerful due to their anisotropic geometry, tunable surface plasmon resonance in the near-infrared (NIR) region, and high photothermal conversion efficiency. These features transform them from passive labels into active nanotransducers capable of amplifying diagnostic signals. Building on these advantages, we developed two AuNPr-based sensing platforms: Thermo Lateral Flow Immunoassay (ThermoLFIA) and Thermo Oligonucleotide-based Lateral Flow Assay (ThermoOLFA). By coupling AuNPrs with thermoresponsive substrates, both systems use localized heat generation to boost analytical sensitivity, enabling visual enhancement far beyond that of conventional gold spheres. ThermoLFIA demonstrated clinically relevant detection of gastrointestinal cancer biomarkers (CEA, CA19-9, VEGF), outperforming standard ELISA tests. In parallel, functionalization of AuNPrs with DNA probes enabled ThermoOLFA to detect SARS-CoV-2 RNA with sensitivity comparable to RT-qPCR, but without amplification steps and within 25 min. This proof-of-concept confirms that plasmonic nanoprisms can drive rapid, portable, and ultrasensitive diagnostics, opening a path toward point-of-care platforms with strong clinical and translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.